Please assess the completion status of the following clinical trial:

Trial Title: INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must have rheumatoid arthritis which has been inadequately controlled with at least one DMARD~* For subjects receiving antimalarials, they must be treated with antimalarials for at least 6 months and receiving a stable daily dose~* For subjects receiving sulfasalazine, they must be treated with Sulfasalazine (SSZ) for at least 6 months and receiving a stable daily dose of no more than 3 grams per day~* For subjects on methotrexate, they must be treated with methotrexate for at least 6 months, and receiving a stable weekly dose of methotrexate between 7.5 and 25 mg~* For subjects on leflunomide, they must be treated with leflunomide for at least 6 months, and receiving a stable dose of leflunomide between 10 to 20 mg~* For subjects receiving corticosteroids, they must be on a dose not to exceed 10 mg of prednisone daily~* Active rheumatoid arthritis at the time of screening defined by the following: 6 or more joints tender or painful on motion and 4 or more swollen joints and at least one of the following two: Erythrocyte sedimentation rate (ESR) greater than or equal to 28 mm/hr or C-reactive protein (CRP) greater than or equal to 7 mg/liter~* Have evidence of lack of risk for tuberculosis~Exclusion Criteria:~* Current or recent viral, bacterial, fungal, parasitic or mycobacterial infection requiring systemic therapy~* History of infected joint prosthesis~* Subjects who have a current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease~* Subjects who have received treatment with the following drugs or drug classes within the specified timeframe: prior treatment with rituximab within 12 months, prior treatment with an oral Janus kinase (JAK) inhibitor, DMARDs or other anti-rheumatic therapies not specified and allowed according to protocol, treatment with any investigational medication within 12 weeks or 5 half-lives (whichever is longer), and treatment with a biologic agent within 12 weeks prior to the first dose of study medication~* Subjects with a past history of neutropenia, thrombocytopenia or anemia requiring transfusion other than at the time of trauma or surgery, and subjects that meet protocol specified laboratory measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB028050 4 mg QD (Type: EXPERIMENTAL): INCB028050 4mg Once daily (QD)
- INCB028050 7 mg QD (Type: EXPERIMENTAL): INCB028050 7mg QD
- INCB028050 10 mg QD (Type: EXPERIMENTAL): INCB028050 10mg QD
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).